Wugen
Business Services · Missouri, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
4260 Forest Park Ave Ste 100, St. Louis,...Phone Number
(636) 385-5306Website
www.wugen.comRevenue
$16.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Wugen
Founded in 2018, Wugen Inc., is a biotechnology company developing a novel CAR-T therapy platform including an "off-the-shelf" fratricide-resistant CAR-T cell therapy for T-cell malignancies. Wugen's state-of-the-art gene editing technologies and cutting-edge CAR-T cell therapy address some of the challenges that have limited the clinical development of allogeneic CAR-T cells. Wugen was founded based on technology licensed from Washington University in St. Louis.Explore more
Wugen Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Wugen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Wugen is spiking on competitors!
Check if Wugen has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Wugen
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Wugen has new funding data
Earning: See what the market has to say on Wugen recently announced quarterly report
Product Launch: Get notified when Wugen launches new products
Click to see if Wugen had a recent Job posting/layoffs
Wugen, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Wugen
Compare insights from companies similar to Wugen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Wugen
$16.3M
51-200
Private
$224.5M
2018
Ayman KabakibiChief Operating Officer & Executive VP, Research & Development
Company Profile Activity
Activity Insights
Wugen is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Wugen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Wugen.
Wugen financials insights
Gather financial insights about Wugen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Private Equity
$115M
Private Equity
$109.5M
Wugen Tech Stack
A closer look at the technologies used by Wugen
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Funding
Funding
Funding
Funding
Wugen News & Media
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
Wugen closed a $115 million equity financing led by Fidelity Management & Research CompanyStartup Wugen raises $115M for 'off-the-shelf' CAR-T | BioPharma Dive
The St. Louis-based biotech hopes to submit an application for its leukemia and lymphoma therapy in 2027, if all goes well in an ongoing trial.Wugen Secures $115 Million to Advance Pivotal Study of First-in-Class Allogeneic CAR-T Therapy, WU-CART-007
Wugen Secures $115 Million to Advance Pivotal Study of First-in-Class Allogeneic CAR-T Therapy, WU-CART-007Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007
Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Wugen
Sign Up For FreeTo access detailed company insights
Founded in 2018, Wugen Inc., is a biotechnology company developing a novel CAR-T therapy platform including an "off-the-shelf" fratricide-resistant CAR-T cell therapy for T-cell malignancies. Wugen's state-of-the-art gene editing technologies and cutting-edge CAR-T cell therapy address some of the challenges that have limited the clinical developme... Read More
